NEW YORK, NY / ACCESSWIRE / January 30, 2018 / U.S. markets posted their worst day of 2018 on Monday as the yield on the benchmark 10-year Treasury note traded at the highest level since April 2014. The Dow Jones Industrial Average fell 0.67 percent to close at 26,439.48, while the S&P 500 Index declined 0.67 percent to close at 2,853.53. The Nasdaq Composite Index dropped 0.52 percent to close at 7,466.51.

“The rebound in the dollar and of course with the 10-year yield at 2.71[%] that’s a little bit of a challenge for the market here, especially if we continue to rise,” said Peter Cardillo, chief market economist at First Standard Financial, according to MarketWatch.

RDI Initiates Coverage on:

Bitcoin Investment Trust
https://rdinvesting.com/news/?ticker=GBTC

Overstock.com, Inc.
https://rdinvesting.com/news/?ticker=OSTK

Bitcoin Investment’s stock jumped 5.88% on Monday, to close the day at $19.14. The stock recorded a trading volume of 4,823,899 shares, which was above its three months average volume of 127,211 shares. In the last year, Bitcoin Investment’s shares have traded in a range of 18.77 – 3,523.00. The stock is currently trading 99.46% below its 52 week high. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $23.02 is greater than its 200-day moving average of $11.90. Shares of Bitcoin Investment have fallen roughly 13.6 percent in the past month.

Access RDI’s Bitcoin Investment Trust Research Report at:
https://rdinvesting.com/news/?ticker=GBTC

On Monday, shares of Overstock.com recorded a trading volume of 3,604,805 shares, which was below the three months average volume of 4,594,122 shares. The stock ended the day 4.16% higher at 77.55. The share price has gained 464.00% from its 52 week low with a 52 week trading range of 13.75 – 89.80. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $72.02 is greater than its 200-day moving average of $40.64. Shares of Overstock.com have gained roughly 21.36 percent in the past month.

Access RDI’s Overstock.com, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OSTK

Our Actionable Research on Bitcoin Investment Trust (OTCMKTS:GBTC) and Overstock.com, Inc. (NASDAQ:OSTK) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 487340

DENVER, CO / ACCESSWIRE / January 30, 2018 / U.S. Nuclear (OTC PINK: UCLE) recently announced it signed a preliminary agreement with MIFTEC, a subsidiary of MIFTI, to become the exclusive contractor to manufacture medical isotope generators in the nuclear medicine market. MIFTI Nuclear Fusion was recognized and awarded by the U.S. Department of Energy, ARPA-E, for their innovative approach and rapid progress towards fusion energy, which could provide a nearly limitless supply of clean, domestic power. The announcement further stated, “MIFTI has shown that its Staged Z-Pinch fusion technique will produce high neutron flux, which in turn can be used to produce large quantities of lower cost medical radioisotopes that are in big demand and diminishing supply.” MIFTI and MIFTEC have created a revolutionary new way to produce large quantities of radioisotopes, and at a lower cost.

Radioisotopes are in short supply and are required for life-saving medical imaging and certain cancer treatments. According to Research and Markets ‘Global Nuclear Medicine Radioisotopes Market – Analysis and Forecasts (2015-2020)’, the market for nuclear medical radioisotopes was expected to be $9.61 billion in 2015 and is expected to reach $17.28 billion by the end of 2020.

The National Academies of Sciences, Engineering, and Medicine issued a report warning of the potential of severe shortages of radioisotopes. Radioisotopes are currently produced in a small number of older nuclear fission reactors that are subject to shut downs resulting in supply interruptions. Sarah Varney, NY Times author reported in her article, Inside the Global Relay Race to Deliver Moly-99, “Nuclear medicine imaging, a staple of American health care since the 1970s, runs almost entirely on Molybdenum-99, a radioisotope produced by nuclear fission of enriched uranium that decays so rapidly it becomes worthless within days. But moly-99, as it’s called, is created in just six government-owned nuclear research reactors – none in the USA raising concerns about the reliability of the supply and even prompting federal scientists to warn of the possibility of severe shortages.”

Three companies dominate the American market for moly-99 – Lantheus, Curium and GE.

They distribute the material to specialized pharmacies around the country where technicians process it into cartridges that dispense the diagnostic imaging agent called technetium-99m. The companies work against a ticking clock. Because of its short half-life, just 66 hours for moly-99 and six hours for the imaging agent, the material must be quickly delivered to hospitals and administered to patients.

Today, there are only two main sources of Moly-99 for use in the United States. They are the National Research Universal Reactor operated by Atomic Energy Canada, Ltd. at its Chalk River Ontario site and the High Flux Reactor operated by the Nuclear Research and Consultancy Group at the Petten, Netherlands site. Both reactors are over 40 years old. The Canadian NRU reactor which supplies 40% of the world’s moly-99 was only recently given a shut- down reprieve until March 31, 2018 subject to relicensing by the Canadian Nuclear Safety Commission. The Netherlands HFR reactor has been forced to shut down on a number of occasions due to financial issues and hazardous waste leakage. The Netherlands plans to replace the HFR Petten reactor with the Pallas reactor. However, construction is not scheduled to finish until 2023 at a whopping cost estimated at 580M Euros.

MIFTEC will fundamentally change the way radiopharmaceuticals are created.

U.S. Nuclear Corp’s partner, MIFTI/MIFTEC developed a unique Staged Z-pinch (SZP) methodology to produce large quantities of radioisotopes. SZP is a safe, reliable, cost-effective, fusion-based process that uses a hydrogen isotope from seawater to create radionuclides without the environmental hazards of highly enriched uranium (HEU) or low enriched uranium (LEU) or the expense of the cyclotron or reactor method currently required to produce these products.

MIFTI/MIFTEC scientists at the University of California, Irvine, have successfully developed and patented a world-changing technology that will solve the current crisis of worldwide shortages in radionuclide/medical isotopes.

The MIFTI website says, “MIFTI knows of no other non-proliferating, fusion-based company currently in the nuclear medicine space. We are well-positioned to fundamentally change how radiopharmaceuticals are produced and distributed, and thus dominate a critical segment of the multi-billion-dollar nuclear medicine industry.”

This patented new technology enables production of large amounts of medical isotopes and can cut the current cost of production by 50%, thereby allowing even greater access to individuals that need them. Because of the very short lives of the radioisotopes, U.S. Nuclear and MIFTEC plan to have their generators operating at strategically placed distribution facilities in the United States that will be close to users and therefore will offer a significantly longer useful lifespan than today’s only options of distant nuclear power plants in Canada and Europe.

The MIFTI website under “Target Markets” says, “The use of nuclear medicine protocols has grown to over 20 million procedures per year in the United States alone. U.S. Nuclear and MIFTEC target markets include over 10,000 hospitals, clinics, laboratories, radio-pharmaceutical companies, and radio-analytical instrument manufacturers worldwide.”

According to their announcement, U.S. Nuclear Corp. and MIFTEC have agreed to U.S. Nuclear initially acquiring a 10% ownership interest in MIFTEC. The companies are open to discussions leading to a larger interest as they move forward as partners dedicated to becoming a major provider of badly needed radioisotopes.

Conclusion

If U.S. Nuclear and MIFTEC successfully produce radioisotopes with the technology they have already demonstrated, they could capture several billion dollars in sales. If U.S. Nuclear owns a 10% interest in the sales, U.S. Nuclear sales (about $2 million reported for 2016) could experience dramatic growth of 5000% for each billion in sales they recognize. That number could increase even further if they increase their ownership in the partnership. Investment risk seems to be mitigated somewhat by the fact that U.S. Nuclear continues to be a leader in its space, and their long history suggests that the company could experience reasonable growth even without the radioisotope opportunity.

If management executes on their new strategy to become the largest provider of lower-cost radioisotopes in a $17 Billion market, the impact to their short-term and long-term market valuation could be dramatic.

About US Nuclear Corp.

U.S. Nuclear Corp is a radiation detection holding company specializing in the development and manufacturing of radiation detection instrumentation. Through three operating divisions (Technical Associates (TA), Overhoff Technology (OTC), and Electronic Control Concepts (ECC), U.S. Nuclear Corp. harbors more than 100 years of combined experience in supplying top of the line instrumentation to any industry utilizing radionuclides. This includes nuclear power plants, national laboratories, government agencies, homeland security, military, universities and schools, research companies, hospitals, medical and dental centers, energy companies, weapons facilities, first responders, local governments, and manufacturing plants.

For more information about U.S. Nuclear Corp., please visit: www.usnuclearcorp.com

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Flathead Business Solutions LLC, which owns tamarackadvisorsinc.com, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Flathead Business Solutions LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Flathead Business Solutions LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit http://tamarackadvisorsinc.com/legal-disclaimer/.

SOURCE: Tamarack Advisors

ReleaseID: 487285

VANCOUVER, BC / ACCESSWIRE / January 30, 2018 / USGS (U.S. Geological Survey) released a report in December 2017, listing 23 metals and minerals deemed critical to the economy and security of the United States. In response to the report, President Trump signed an executive order to create a strategy to reduce the Nation’s reliance on critical minerals principally imported and used to create everything from laptops to smartphones and electric vehicles. This executive order was welcomed by U.S. based lithium mining companies as a way to start moving production away from Lithium Triangle in Argentina, Bolivia and Chile.

With over 50% of the U.S.’s annual lithium being imported, companies that could benefit from Trump’s new executive order are Standard Lithium Ltd. (TSX-V: SLL) (FRA:S5L), Albemarle Corporation (ALB) (STLHF), Nemaska Lithium Inc. (NMX) (NMKEF) (N0T), Albemarle Corporation (ALB), Advantage Lithium Corp. (AAL) (AVLIF) (14D), and Lithium Americas Corp. (LAC) (LACDF).

Standard Lithium Ltd. (TSX-V: SLL) (FRA: S5L) (OTCQX: STLHF) recently signed a $20 million bought deal private placement agreement with Canaccord Genuity Corp. The funding will help fast track the build out of Standard Lithium’s proposed pilot plant in Smackover, Arkansas. This demonstration scale pilot plant will be adjacent to an existing chemical production facility and will be able process brine from a variety of brine streams including tail brines from the Smackover Formation, which is one of the world’s largest brine deposits. The plant will also be used to process brine transported via railway from the Bristol Dry Lake Project in California.

Dr. Andy Robinson, President of Standard Lithium stated,”The location of the Pilot Plant could not be more favourable, as we will have direct access to the tail brine feed into the site, all necessary utilities, and the access to the services of an existing workforce of skilled and trained brine handling and processing technicians and engineers, all within an existing permitted and fenced brine processing site.”

In addition to the continuously operation demonstration pilot plant, Standard Lithium also recently signed an Option Agreement with TETRA Technologies Inc. (NYSE:TTI). The agreement allows for exploration, production, and lithium extraction rights on up to 33,000 acres of brine leases in the productive areas of the Smackover Formation in Southern Arkansas.

Smackover Formation Project Highlights:

– Up to 33,000 acres of brine leases in key brine production fairway in southern Arkansas, adjacent to producing Albemarle leases;

– Historical data from Standard Lithium lease area shows 370-424 mg/L lithium in brines (Moldovanyi and Walter, 1992);

– Arkansas currently produces the equivalent of 42.6 million m3 (9,380,000,000 gallons) of brine per year (based on Arkansas Oil and Gas Commission reported average brine production from 2010-2016), almost entirely from the Smackover Formation;

– Low risk, well understood geology and chemistry;

– Significant infrastructure, roads, power, water, trained workforce in region; and

– Existing brine extraction, processing and re-injection permitting regime.

Robert Mintak, the CEO of Standard Lithium, elaborates, “In our search for opportunities of significance, this is one that could really move the needle. We believe the Smackover may be one of the lithium industry’s most promising regions to develop, given the potential resource size and large-scale brine-handling infrastructure in the region.”

Other lithium producers

Nemaska Lithium Inc. (NMX) (NMKEF) (N0T) is not among the U.S.-based lithium producers. Instead, Nemaska is headquartered in Quebec, Canada. There, Nemaska is developing one of the world’s most important spodumene lithium hard rock deposits. This is largely coming from the Whabouchi lithium mine, where it will be processed at the lithium hydroxide/carbonate processing plant in Quebec. The plant, currently under construction, will transform spodumene concentrate into high purity lithium hydroxide and lithium carbonate. These products will then be able to be used in lithium-ion batteries.

Albemarle Corporation (ALB) is a global producer of lithium but also has lithium production sites in the U.S, such as its Silver Peak plant in Nevada. While Albemarle is currently one of the world’s largest producers of lithium raw material, Trump’s order may shift U.S. focus to those lithium producers that are predominantly located in the U.S. alone.

Advantage Lithium Corp. (AAL) (AVLIF) (14D) may be one of the lithium producers that gets pushed out of U.S. importation if Trump follows through on his order. Advantage Lithium is mainly focused on regions of Argentina for lithium production. Currently, Argentina is a top producer of lithium. However, as Trump’s order may shift greater focus to U.S.-based lithium production, Advantage Lithium may become less of a player than it currently is.

Lithium Americas Corp. (LAC) (LACDF) has projects based in Argentina and Nevada. The company is continuing to advance both projects this year, recently providing an update on on their Cauchari-Olaroz project in Jujuy, Argentina and their Lithium Nevada resource in the McDermitt Caldera of northern Nevada. Stateside, Lithium Americas is planning for a further 2018 exploration drill program focused on mapping the extent of the Lithium Nevada deposit.

As stated in the USGS report, the U.S. “is not a major producer at present but has significant lithium resources.” A positive statement for Standard Lithium and the other companies highlighted above to help shift America’s reliance on lithium to a domestic level.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated one thousand eight hundred dollars for its efforts in distributing the Standard Lithium Ltd. article. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article.

Contact:

Aaron Bodnar
aaron@baystreet.ca

SOURCE: Baystreet.ca Media Corp.

ReleaseID: 487315

Stock Monitor: Fair Isaac Post Earnings Reporting

LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free earnings report on Aspen Technology, Inc. (NASDAQ: AZPN) (“AspenTech”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AZPN. The Company reported its second quarter fiscal 2018 operating and financial results on January 24, 2018. The software maker outperformed top- and bottom-line expectations, and raised its revenue, operating income, earnings, and free cash flow guidance for FY18. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Fair Isaac Corporation (NYSE: FICO), which also belongs to the Technology sector as the Company Aspen Technology. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=FICO

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Aspen Technology most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AZPN

Earnings Highlights and Summary

For the second quarter of the fiscal year 2018 (Q2 FY18) ended December 31, 2017, AspenTech’s total revenues came in at $124.90 million, up 4.1% compared to $119.93 million in Q2 FY17. The Company’s revenue numbers topped analysts’ estimates of $121.9 million.

During Q2 FY18, AspenTech’s subscription and software revenue gained 4.3% to $117.7 million compared to $112.9 million in Q2 FY17. The Company’s services and other revenue was $7.2 million in the reported quarter compared to $7.0 million in the year ago same period.

For Q2 FY18, AspenTech reported income from operations of $54.5 million compared to $56.1 million for Q2 FY17. The Company’s non-GAAP income from operations, which added the impact of stock-based compensation expenses, amortization of intangibles associated with acquisitions, litigation judgments, acquisition-related fees, and non-capitalized acquired technology, was $62.2 million for the reported quarter versus $60.9 million in the year ago comparable period.

AspenTech’s GAAP operating margin was 43.6% in Q2 FY18 compared to 46.7% in Q2 FY17. The Company’s non-GAAP operating margin was 49.8% in the reported quarter compared to 50.8% in the year earlier corresponding quarter.

For Q2 FY18, AspenTech reported a net income of $38.08 million, or $0.52 per diluted share, compared to $37.01 million, or $0.48 per diluted share, in Q2 FY17. The Company’s non-GAAP net income totaled $43.0 million, or $0.59 per share, for the reported quarter compared to non-GAAP net income of $40.2 million, or $0.52 per share, in the prior year’s same quarter. AspenTech’s earnings came in ahead of Wall Street’s estimates of $0.50 per share.

AspenTech’s annual spend, defined as the Company’s annualized value of all term license and maintenance contracts at the end of a quarter, was approximately $469 million at the end of Q2 FY17, increasing 4.2% on a y-o-y basis.

Cash Matters

As of December 31, 2017, AspenTech had cash and marketable securities of $48.7 million and borrowings of $151.0 million. During Q2 FY18, the Company generated $42.4 million in cash flow from operations and $42.2 million in free cash flow. AspenTech’s deferred revenue balance was $258.7 million at the end of Q2 FY18, representing a 7.2% increase on a y-o-y basis.

During Q2 FY18, AspenTech repurchased approximately 756,000 shares of its common stock for $50.0 million.

Outlook

For the third quarter of the fiscal year 2018, AspenTech is forecasting revenue to be in the range of $120 million to $122 million; non-GAAP operating income to be in the band of $52 million to $54 million; and non-GAAP earnings per share to be $0.48 to $0.50. On a GAAP basis, the Company is estimating operating income in the range of $46 million to $48 million, and income per share of $0.42 to $0.44.

For the fiscal year 2018, AspenTech raised its revenue expectations in the band of $490 million to $495 million. The Company updated its GAAP operating income guidance to a range of $204 million to $209 million, with GAAP net income estimated to be in the band of $1.90 to $1.95 compared to its previous guidance of $1.71 to $1.76.

AspenTech raised its non-GAAP operating income guidance to $231 million to $236 million, and now expects non-GAAP income per share in the range of $2.16 to $2.21, which compares to its previous guidance of $1.92 to $1.97.

AspenTech also increased its free cash flow forecasts to be in the band of $190 million to $195 million versus its previous guidance of $180 million to $185 million.

Stock Performance Snapshot

January 29, 2018 – At Monday’s closing bell, Aspen Technology’s stock marginally declined 0.56%, ending the trading session at $79.67.

Volume traded for the day: 599.61 thousand shares, which was above the 3-month average volume of 425.12 thousand shares.

Stock performance in the last month – up 20.66%; previous three-month period – up 19.39%; past twelve-month period – up 49.62%; and year-to-date – up 20.35%

After yesterday’s close, Aspen Technology’s market cap was at $5.76 billion.

Price to Earnings (P/E) ratio was at 36.40.

The stock is part of the Technology sector, categorized under the Business Software & Services industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 487352

Stock Monitor: American Electric Power Post Earnings Reporting

LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free research report on Azure Power Global Ltd (NYSE: AZRE). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AZRE as the Company’s latest news hit the wire. On January 26, 2018, the Company announced that it has won a 11.35 megawatts (MWs) solar rooftop power project. The solar rooftops will be spread across 152 schools and six states in India, including Uttar Pradesh, Madhya Pradesh, Rajasthan, Karnataka, Chhattisgarh, and Kerala. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for American Electric Power Company, Inc. (NYSE: AEP), which also belongs to the Utilities sector as the Company Azure Power Global. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=AEP

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Azure Power Global most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AZRE

The Company will sign the power purchase agreement with Navodaya Vidyalaya Samiti, an autonomous body under Ministry of Human Resource Development, Government of India. Azure Power qualifies for a capital incentive from Navodaya Vidyalaya Samiti, which is expected to result in a weighted average levelized tariff of INR 4.97 (~US cents 7.7) per kWh.

Azure Power’s Recent Project to Electrify Government Buildings of Udaipur Smart City

On January 24, 2018, the Company won the mandate to install the first ever 2 MW rooftop solar project for Udaipur Smart City Limited (USCL). As per the mandate, Azure Roof Power would design, supply, install, commission, and operate the grid connected rooftop solar PV project for 25 years at various Government buildings in Udaipur, in the state of Rajasthan in western India.

Solar Power Projects Won in 2017

In November 2017, the Company announced its foray into rural electrification through mini and micro grids in the eastern state of Jharkhand, India. Azure Power won a project to electrify 320 households across 11 villages through development of mini and micro grids.

Azure Power won a 250 MW solar project in an auction conducted by NTPC Vidyut Vyapar Nigam (NVVN), a wholly owned subsidiary of the Government of India’s largest power utility, National Thermal Power Corporation (NTPC), in October 2017.

In September 2017, the Company won a 260 MW solar project in an auction conducted by Gujarat Urja Vikas Nigam Ltd (GUVNL). The Company also won a 50 MW solar project in an auction conducted by Solar Energy Corporation of India (SECI), a company of the Ministry of New and Renewable Energy, Government of India.

In March 2017, Azure Power won a 46 MWs of solar rooftop projects across eleven states pan India for Indian Railways, owned and operated by the Government of India through the Ministry of Railways. The Company won an additional 20 MWs of solar rooftop projects for Indian Railways in September 2017.

About Azure Roof Power

Azure Roof Power offers superior rooftop solar power solutions for commercial, industrial, government, and institutional customers in cities across India to lower their energy bill and meet their greenhouse gas (GHG) emission reduction targets. With over 150 MWs of high quality, operating and committed solar assets across 20 states, it has one of the largest rooftop portfolios in the country. Azure Roof Power’s customer base includes Government of India backed entities, large commercial real estate companies, a leading global chain of premium hotels, distribution companies in smart cities, warehouses, Delhi Metro Rail Corporation, Indian Railways, a Delhi water utility company, and various Government of India Ministries.

About Azure Power Global Ltd

Founded in 2008, Azure Power Global is a leading independent power producer and developer of solar energy with the mission to be the lowest-cost power producer in the world. The Company, together with its subsidiaries, engages in the development, construction, ownership, operation, maintenance, and management of solar power plants in India. Azure Power Global is based in New Delhi, India.

Stock Performance Snapshot

January 29, 2018 – At Monday’s closing bell, Azure Power Global’s stock slightly fell 0.30%, ending the trading session at $16.50.

Volume traded for the day: 4.37 thousand shares.

Stock performance in the last month – up 19.31%; previous three-month period – up 7.07%; past six-month period – up 5.36%; and year-to-date – up 16.20%

After yesterday’s close, Azure Power Global’s market cap was at $425.87 million.

The stock is part of the Utilities sector, categorized under the Electric Utilities industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 487353

LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free research report on CASI Pharmaceuticals, Inc. (NASDAQ: CASI). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CASI as the Company’s latest news hit the wire. On January 26, 2018, the Company declared that it has acquired a portfolio of abbreviated new drug applications (ANDAs) from Sandoz Inc. The portfolio includes 25 ANDAs approved by the US Food and Drug Administration (FDA), one ANDA that FDA tentatively approved, and three ANDAs that are pending FDA approval. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, CASI Pharmaceuticals most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CASI

Acquisition Likely to Enhance CASI Pharma’s Strategic Focus to Commercialize Quality Drug Candidates in China

The Company intends to select and commercialize certain products from the portfolio that have unique market opportunity and cost-effective manufacturing in China and/or in the US. The acquisition will enhance CASI Pharma’s strategic focus to build a robust pipeline. The Company will transfer a select subset of products from the portfolio to lower cost manufacturing facilities in China and contemplates submitting CBE-30 supplement or Prior Approval Supplement (PAS) to the approved/pending ANDAs as soon as possible.

The acquired application also includes entecavir, an antiviral medication used in the treatment of hepatitis B viral infection (HBV), which in China accounts for more than half of the estimated 700,000 HBV-related deaths worldwide each year. CASI Pharma also intends to develop and market on its own priority products from the portfolio and may partner the remaining US ANDA assets to strategic partners.

CASI Pharma to Launch Certain Products Acquired from Sandoz’s Portfolio in China

Ken Ren, Ph.D., Chief Executive Officer of CASI Pharma, stated that with FDA-approved ANDA status and the high-quality standards of Sandoz, the Company anticipates leveraging the Chinese FDA’s (CFDA) more recent regulations to accept western pharmaceutical and clinical data for rapid entry into China’s market while being competitive in the marketplace. Ken added that this is an exciting and unprecedented time in the CFDA regulatory landscape, against a backdrop of soaring demand in China for high quality import pharmaceuticals. The Company is confident in its ability to launch certain products in China that it has acquired from the Sandoz portfolio, along with its launch of EVOMELA®, MARQIBO®, and ZEVALIN® all of which are in various stages of CFDA review.

About FDA-Approved Abbreviated New Drug Application

ANDA contains data which is submitted to FDA for the review and potential approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, lower cost alternative to the brand-name drug it references.

About CASI Pharmaceuticals, Inc.

Founded in 1991, CASI Pharma is a biopharmaceutical company focused on the acquisition, development, and commercialization of quality pharmaceuticals and innovative therapeutics addressing CANCER and other unmet medical needs for the global market, with a focus on greater China and the US. The Company is headquartered in Rockville, Maryland.

About Sandoz Inc.

Established in 1886 and based in Holzkirchen, Bavaria, Sandoz (formerly known as Geneva Pharmaceuticals Technology Corporation) is a global leader in generic pharmaceuticals and biosimilars. The Company is a subsidiary of Novartis Group.

Stock Performance Snapshot

January 29, 2018 – At Monday’s closing bell, CASI Pharmaceuticals’ stock climbed 6.46%, ending the trading session at $4.12.

Volume traded for the day: 525.61 thousand shares, which was above the 3-month average volume of 489.53 thousand shares.

Stock performance in the last month – up 29.15%; previous three-month period – up 100.00%; past twelve-month period – up 188.11%; and year-to-date – up 26.77%

After yesterday’s close, CASI Pharmaceuticals’ market cap was at $268.05 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 487354

Stock Monitor: Intuitive Surgical Post Earnings Reporting

LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free earnings report on Varian Medical Systems, Inc. (NYSE: VAR) (“Varian”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VAR. The Company posted its first quarter fiscal 2018 (Q1 FY18) financial results on January 24, 2018. The leading medical devices and software products manufacturer’s revenues and earnings surpassed market expectations. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Intuitive Surgical, Inc. (NASDAQ: ISRG), which also belongs to the Healthcare sector as the Company Varian Medical Systems. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ISRG

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Varian Medical Systems most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=VAR

Earnings Highlights and Summary

During the first quarter of the fiscal year 2018, Varian posted net sales of $678.50 million compared to $601.50 million in Q1 FY17, reflecting an increase of 12.80%. Varian’s sales growth was primarily backed by higher linac systems sales in the Oncology Operating segment. The Company’s revenue numbers beat analysts’ estimates of $639.47 million.

Varian’s gross profit was $302.8 million in Q1 FY18 compared to $267.00 million in Q1 FY17, increasing 13.41% on a y-o-y basis. The Company’s selling, general, and administrative expenses (SG&A) amounted to $125.50 million in the reported quarter compared to $161.40 million in the year ago same period, decreasing 22.24% on a y-o-y basis. The Company’s operating profit was $121.40 million in Q1 FY18 compared to $17.40 million in Q1 FY17, soaring 597.70% on a y-o-y basis.

Varian’s net loss was $112.30 million, or $1.22 loss per share, in Q1 FY18 compared to a net income of $13.90 million, or $0.15 per share, in Q1 FY17. The decline was due to the impact of the new Tax Cuts and Jobs Act. The Company’s adjusted earnings were $1.06 in the reported quarter compared to $0.50 in Q1 FY17, surging 112% on a y-o-y basis. The increase in EPS was attributed to a strong growth, operational execution, and the non-recurrence of a prior-year accounts receivable in the Particle Therapy business. The Company’s adjusted earnings numbers beat analysts’ estimates of $0.98.

Segment Details

Varian has two business segments, namely: (i) Oncology Systems segment, and (ii) Particle Therapy segment.

The Oncology Systems segment reported net sales of $649.40 million in Q1 FY18 compared to $571.20 million in Q1 FY17, reflecting a growth of 13.69% versus the year ago comparable period. The segment’s gross orders were $619.90 million in the reported quarter compared to $576.70 million in Q1 FY17, increasing 7.49% on a y-o-y basis. The segment’s gross orders in the Americas increased 2% on a y-o-y basis. In Europe, the Middle-East, and Africa (EMEA), Oncology Systems’ gross orders rose 19% in USD terms, and 13% in constant currency, to $190 million, while in Asia/Pacific (APAC), gross orders advanced 6% on a y-o-y basis.

The Particle Therapy segment posted net sales of $29.10 million in Q1 FY18 compared to $30.30 million in Q1 FY17, decreasing 3.96% on a y-o-y basis. The segment’s gross orders were $46.20 million in Q1 FY18 compared to $4.30 million in Q1 FY17. During the reported quarter, the Company booked ProBeam Compact orders from the University of Alabama at Birmingham and the Sylvester Comprehensive Cancer Center at the University of Miami, totaling $46.00 million.

Cash Matters

As on December 29, 2017, Varian had cash and cash equivalents of $822.60 million. The Company’s cash inflow from operating activities was $179.00 million in the reported quarter compared to $82.20 million in Q1 FY17. During the reported quarter, Varian repurchased 525,000 shares of its common stock for $57.00 million.

Outlook

For the fiscal year 2018, Varian is anticipating sales growth to be in the range of 4.00% – 7.00%. The Company expects adjusted EPS to be in the band of $4.24 – $4.36. The Company’s cash flow from operations is projected to be in the range of $475.00 million – $550.00 million.

Stock Performance Snapshot

January 29, 2018 – At Monday’s closing bell, Varian Medical Systems’ stock was slightly down 0.69%, ending the trading session at $128.57.

Volume traded for the day: 959.06 thousand shares, which was above the 3-month average volume of 773.40 thousand shares.

Stock performance in the last month – up 15.72%; previous three-month period – up 23.14%; past twelve-month period – up 63.50%; and year-to-date – up 15.67%

After yesterday’s close, Varian Medical Systems’ market cap was at $11.82 billion.

Price to Earnings (P/E) ratio was at 92.56.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 487347

Stock Monitor: Fastenal Post Earnings Reporting

LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free earnings report on W.W. Grainger, Inc. (NYSE: GWW) (“Grainger”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=GWW. W.W. Grainger reported its fourth quarter and fiscal 2017 operating and financial results on January 24, 2018. The seller of maintenance and other supplies outperformed top- and bottom-line expectations. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Fastenal Company (NASDAQ: FAST), which also belongs to the Services sector as the Company W.W. Grainger. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=FAST

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, W.W. Grainger most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=GWW

Earnings Highlights and Summary

Grainger’s sales for the fourth quarter of 2017 totaled $2.63 billion, were up 7% versus sales of Q4 2016 of $2.47 billion. The Company’s sales growth consisted of an 11% increase from volume, partially offset by a 3% decline from price and a 1% decline from the divesture of a specialty business. Grainger’s sales exceeded analysts’ estimates of $2.57 billion of sales.

For FY17, Grainger’s sales totaled $10.42 billion compared to sales of $10.14 billion in FY16.

During Q4 2017, Grainger’s operating earnings of $239.94 million surged 38% compared to operating earnings of $174.23 million in Q4 2016, driven by higher sales and gross profit dollars along with lower restructuring costs and other charges versus the prior year. Grainger’s gross profit margin for the reported quarter decreased 1.3%, primarily driven by price deflation in the United States.

During Q4 2017, the Company reported net income attributable to Grainger of $151.06 million, or $2.63 per diluted share, compared to $60.67 million, or $1.01 per diluted share, in Q4 2016. On an adjusted basis, the Company’s earnings advanced 20% to $2.94 per diluted share versus $2.45 per share in the year ago same period. Grainger’s earnings surpassed Wall Street’s estimates of $2.18 per share.

For FY17, Grainger reported net earnings of $585.73 million, or $10.02 per diluted share, compared to earnings of $605.93 million, or $9.87 per diluted share, in FY16.

W.W. Grainger’s Segment Results

Grainger has two reportable business segments: United States and Canada, which represented approximately 79% of the Company’s sales for the reported quarter. The remaining operating businesses were located in Europe, Asia, and Latin America.

During Q4 2017, Grainger’s sales in the US segment grew 5% to $1.99 billion on a y-o-y basis. The segment’s sales increase consisted of a volume increase of 11%, partially offset by 5% from price and a 1% decline from the divesture of a specialty business. The US segment operating earnings advanced 16% to $290.52 million on a y-o-y basis, driven by higher sales and lower restructuring charges.

For Q4 2017, Grainger’s sales in the Canada segment gained 5% in US dollars to $189.43 million on a y-o-y basis. The segment’s sales growth consisted of 5% from favorable foreign exchange and a 4% increase from price, partially offset by a 4% decrease from volume. The Canada segment operating loss was $17 million in the reported quarter versus a $10 million loss in the year ago same period, driven by higher operating expenses.

Cash Flow

Grainger’s operating cash flow for Q4 2017 was $336 million versus $335 million in Q4 2016. The Company used the cash generated during the reported quarter to invest in the business, pay down debt and return cash to shareholders through share repurchase and dividends.

Grainger’s capital expenditures were $46 million in Q4 2017 versus $71 million in Q4 2016. In the reported quarter, the Company returned $248 million to shareholders through $79 million in dividends and $169 million to buy back 855,000 shares of stock. Grainger’s free cash flow was $299 million for Q4 2017 versus $271 million in Q4 2016.

Stock Performance Snapshot

January 29, 2018 – At Monday’s closing bell, W.W. Grainger’s stock dropped 3.78%, ending the trading session at $274.48.

Volume traded for the day: 1.55 million shares, which was above the 3-month average volume of 1.00 million shares.

Stock performance in the last month – up 15.81%; previous three-month period – up 36.44%; past twelve-month period – up 7.06%; and year-to-date – up 16.18%

After yesterday’s close, W.W. Grainger’s market cap was at $15.71 billion.

Price to Earnings (P/E) ratio was at 31.59.

The stock has a dividend yield of 1.87%.

The stock is part of the Services sector, categorized under the Industrial Equipment Wholesale industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 487348

LONDON, UK / ACCESSWIRE / January 30, 2018 / Active-Investors.com has just released a free earnings report on Whirlpool Corp. (NYSE: WHR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=WHR. Whirlpool reported its fourth quarter and fiscal 2017 operating and financial results on January 24, 2018. The home appliance maker saw sales growth on a y-o-y basis, and the Company also provided guidance for the full year fiscal 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Whirlpool most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=WHR

Earnings Highlights and Summary

Whirlpool’s Q4 2017 net sales were $5.70 billion, reflecting growth of 1% compared to sales of $5.66 billion in Q4 2016. Excluding the impact of currency, the Company’s sales fell 1.6% on a y-o-y basis. The Company’s revenue number lagged behind analysts’ estimates of $5.83 billion.

Whirlpool reported GAAP operating profit of $267 million, or 4.7% of sales, in Q4 2017 compared to $341 million, or 6.0% of sales, in Q4 2016. The Company’s ongoing operating profit was $392 million, or 6.9% of sales, in the reported quarter compared to $431 million, or 7.6% of sales, in the year ago corresponding period.

Whirlpool’s GAAP net loss was $268 million, or $3.69 per diluted share, including a one-time non-cash charge of approximately $420 million related to tax reform for Q4 2017 compared to GAAP net earnings of $180 million, or $2.36 per diluted share, for Q4 2016. The Company’s ongoing earnings per diluted share were $4.10 in the reported quarter, compared to $4.33 in the prior year same period. Whirlpool’s earnings beat Wall Street’s estimates of $3.99 per share.

For the full year 2017, Whirlpool’s net sales were $21.3 billion compared to $20.7 billion in 2016. Excluding the impact of currency, the Company’s sales increased 1.5% on a y-o-y basis.

Whirlpool’s GAAP net earnings per diluted share were $4.70 in Q4 2017 compared to $11.50 in Q4 2016. The Company’s GAAP net earnings per diluted share in 2017 were adversely impacted by a one-time non-cash charge of approximately $420 million related to tax reform. Whirlpool’s ongoing earnings per diluted share were $13.74 compared to $14.06 in the prior year.

Regional Review

For Q4 2017, Whirlpool North America reported net sales were $3.1 billion, almost unchanged on a y-o-y basis. Excluding the currency impact, the segment’s sales fell 0.8%. The region posted operating profit of $368 million, or 11.8% of sales, in the reported quarter compared to $349 million, or 11.2% of sales, in the prior year same period.

Whirlpool Europe, Middle-East, and Africa (EMEA)’s net sales grew 1.5% to $1.4 billion in Q4 2017. Excluding the impact of currency, the segment’s sales decreased 5.6% on a y-o-y basis. The region reported GAAP operating profit of $4 million, or 0.3% of sales, for Q4 2017 compared to GAAP operating profit of $17 million, or 1.3% of sales, in Q4 2016. Ongoing segment operating profit was $4 million, or 0.3% of sales, versus $45 million, or 3.3% of sales, in the year ago comparable period.

Whirlpool Latin America reported net sales of $905 million in Q4 2017 compared to $860 million in Q4 2016, reflecting growth of 5.2%. Excluding the impact of currency, the segment’s sales increased 4.4%. The region posted operating profit of $64 million, or 7.1%, in the reported quarter compared to $71 million, or 8.3% of sales, in the year earlier same quarter.

For Q4 2017, Whirlpool Asia reported net sales of $333 million compared to $352 million in Q4 2016. Excluding the impact of currency, the segment’s sales fell 8.3%. The region reported GAAP operating loss of $1 million, or 0.4% of sales, in Q4 2017 versus GAAP operating profit of $18 million, or 4.9% of sales, in the year earlier comparable quarter.

Cash Matters

For the twelve months ended December 31, 2017, Whirlpool reported cash provided by operating activities of $1.3 billion compared to $1.2 billion in the year ago same period. The Company reported free cash flow of $707 million for 2017 compared to $630 million in the prior year.

Outlook

For the full-year 2018, Whirlpool is forecasting to generate cash from operating activities of approximately $1.7 billion to $1.8 billion and free cash flow of approximately $1.0 billion to $1.1 billion. For FY18, Whirlpool is projecting GAAP earnings per diluted share of $12.45 to $13.45 and ongoing earnings per diluted share of $14.50 to $15.50.

Stock Performance Snapshot

January 29, 2018 – At Monday’s closing bell, Whirlpool’s stock fell 1.87%, ending the trading session at $182.50.

Volume traded for the day: 928.15 thousand shares, which was above the 3-month average volume of 904.11 thousand shares.

Stock performance in the last month – up 7.30%; previous three-month period – up 13.00%; past twelve-month period – up 6.82%; and year-to-date – up 8.22%

After yesterday’s close, Whirlpool’s market cap was at $13.30 billion.

Price to Earnings (P/E) ratio was at 40.46.

The stock has a dividend yield of 2.41%.

The stock is part of the Consumer Goods sector, categorized under the Appliances industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 487349